China Shineway Pharmaceutical Group Ltd banner
C

China Shineway Pharmaceutical Group Ltd
HKEX:2877

Watchlist Manager
China Shineway Pharmaceutical Group Ltd
HKEX:2877
Watchlist
Price: 9.79 HKD 0.1%
Market Cap: HK$8.1B

China Shineway Pharmaceutical Group Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Shineway Pharmaceutical Group Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
C
China Shineway Pharmaceutical Group Ltd
HKEX:2877
Revenue
¥3.1B
CAGR 3-Years
-7%
CAGR 5-Years
3%
CAGR 10-Years
4%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Revenue
¥15B
CAGR 3-Years
17%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Revenue
¥32.6B
CAGR 3-Years
15%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Revenue
¥41.2B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
7%
Zhejiang Nhu Co Ltd
SZSE:002001
Revenue
¥22.3B
CAGR 3-Years
12%
CAGR 5-Years
17%
CAGR 10-Years
19%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Revenue
¥5.8B
CAGR 3-Years
94%
CAGR 5-Years
37%
CAGR 10-Years
N/A
No Stocks Found

China Shineway Pharmaceutical Group Ltd
Glance View

In the bustling world of pharmaceuticals, China Shineway Pharmaceutical Group Ltd. stands as a noteworthy player adeptly navigating the intricate channels of traditional Chinese medicine and modern pharmaceutical practices. Established in 1996, the company has rooted its foundation in the age-old wisdom of Chinese herbal medicine, while seamlessly integrating contemporary manufacturing methods. Headquartered in the industrial city of Shijiazhuang, Shineway has grown into one of China's top pharmaceutical enterprises, distinguished by its commitment to quality and innovation in healthcare solutions. At the heart of Shineway's operations is a robust production line that focuses on the development and distribution of herbal-based medicines, granules, and injections that cater to a diverse array of health needs, ranging from respiratory ailments to cardiovascular conditions. Shineway's journey to profitability hinges on a well-crafted strategy of combining the trusted efficacy of traditional Chinese cures with rigorous scientific validation and modern production processes. With a comprehensive distribution network spanning domestic markets and cautiously expanding international borders, the company has managed to effectively channel its products through hospitals, clinics, and retail pharmacies. Their financial success is further bolstered by substantial investments in technology and research, allowing Shineway to continuously refine its offerings and maintain competitive prices. In an era where the global health landscape is constantly evolving, China Shineway Pharmaceutical Group Ltd. thrives by striking a delicate balance between preserving traditional medicinal heritage and embracing the advancements of contemporary pharmaceutical sciences, thereby securing a steady revenue stream while fostering broader acceptance of traditional Chinese medicine across the globe.

Intrinsic Value
16.3 HKD
Undervaluation 40%
Intrinsic Value
Price HK$9.79
C

See Also

What is China Shineway Pharmaceutical Group Ltd's Revenue?
Revenue
3.1B CNY

Based on the financial report for Dec 31, 2025, China Shineway Pharmaceutical Group Ltd's Revenue amounts to 3.1B CNY.

What is China Shineway Pharmaceutical Group Ltd's Revenue growth rate?
Revenue CAGR 10Y
4%

Over the last year, the Revenue growth was -17%. The average annual Revenue growth rates for China Shineway Pharmaceutical Group Ltd have been -7% over the past three years , 3% over the past five years , and 4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett